Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3lTVKDU
via IFTTT